A Pilot Study of 18F-DCFPyL-PSMA PET in Patients Receiving 177Lu-Vipivotide Tetraxetan Therapy for Metastatic Castrate-resistant Prostate Cancer
Latest Information Update: 05 Feb 2026
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
Most Recent Events
- 29 Jan 2026 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 29 Jan 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
- 05 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.